SpyGlass Pharma, Inc. (SGP)
NasdaqGS · USD · Healthcare · Biotechnology
$30.70 (+2.64%) as of
Key statistics
- Market cap
- 1.03B
- Forward P/E
- -10.91
- EPS (TTM)
- -2.51
- Dividend yield
- 0.00%
- 52-week range
- 17.06 – 32.44
- Profit margin
- 0.00%
- Analyst target
- $44.00
- Volume
- 8.27k
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Irvine, CA, United States
- Employees
- 76
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- Backblaze, Inc. (BLZE)
- Goldman Sachs Group, Inc. (The) (GS-PA)
- Nuveen Dynamic Municipal Opportunities Fund (NDMO)
- CapsoVision, Inc. (CV)
- European Wax Center, Inc. (EWCZ)
- Matrix Service Company (MTRX)
- Neuberger Berman Income Funds - Neuberger Next Generation Connectivity Fund Inc. (NBXG)
- Strata Critical Medical, Inc. (SRTA)